Head-to-head · free
TScan Therapeutics, Inc. vs TransMedics Group, Inc.
TCRX vs TMDX — return on capital, cash generation, margins and balance sheet side by side.
TCRX
0 / 8
measures where TCRX leads
TMDX
8 / 8
measures where TMDX leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | TCRX · FY2025 | TMDX · FY2025 |
|---|---|---|
| Revenue | $10.3M | $605.5M |
| Net income | (129.8M) | $190.3M |
| Revenue growth (yearly, multi-year) | 0.5% | 111.5% |
| Free cash flow | (139.7M) | $133.6M |
| Free cash flow margin | -1353.3% | 22.1% |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -71.3% | 54.2% |
| Gross margin | — | 59.9% |
| Operating margin | -1315.4% | 17.9% |
| Net debt / EBITDA | 0.90x | 0.18x |
Figures are as reported by each company; latest fiscal year shown.
Where TScan Therapeutics, Inc.'s cash went (FY2025)
- Capital spending
- $4.4M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where TransMedics Group, Inc.'s cash went (FY2025)
- Capital spending
- $59.3M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free